Key Record Dates
| ClinicalTrials.gov Identifier: | NCT04209205 |
|---|---|
| Brief Title: | Study to Demonstrate the Efficacy, Safety and Tolerability of Intravenous Secukinumab up to 52 Weeks in Subjects With Active Psoriatic Arthritis (INVIGORATE 2) |
| First Submitted : | October 30, 2019 |
| First Submitted that Met QC Criteria : | December 19, 2019 |
| First Posted : | December 24, 2019 |
| Certification/Extension First Submitted : | October 4, 2022 |
| Certification/Extension First Posted : | |
| Last Update Submitted that Met QC Criteria : | April 13, 2023 |
| Last Update Posted : | April 21, 2023 |